KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer

Inhibitors that target the receptor tyrosine kinase (RTK)/Ras/mitogen-activated protein kinase (MAPK) pathway have led to clinical responses in lung and other cancers, but some patients fail to respond and in those that do resistance inevitably occurs (Balak et al., 2006; Kosaka et al., 2006; Rudin...

Descripción completa

Detalles Bibliográficos
Autores principales: Krall, Elsa B, Wang, Belinda, Munoz, Diana M, Ilic, Nina, Raghavan, Srivatsan, Niederst, Matthew J, Yu, Kristine, Ruddy, David A, Aguirre, Andrew J, Kim, Jong Wook, Redig, Amanda J, Gainor, Justin F, Williams, Juliet A, Asara, John M, Doench, John G, Janne, Pasi A, Shaw, Alice T, McDonald III, Robert E, Engelman, Jeffrey A, Stegmeier, Frank, Schlabach, Michael R, Hahn, William C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: eLife Sciences Publications, Ltd 2017
Materias:
Cancer Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5305212/
https://www.ncbi.nlm.nih.gov/pubmed/28145866
http://dx.doi.org/10.7554/eLife.18970

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5305212/
https://www.ncbi.nlm.nih.gov/pubmed/28145866
http://dx.doi.org/10.7554/eLife.18970

Ejemplares similares